


Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-9CDF5798-380A-490A-B56F-D2BB9ABBE39E_2_en-US
DOI: https://doi.org/10.31003/USPNF_M82120_02_01
DOI Ref: 3tb22

© 2025 USPC
Do not distribute

Theophylline



$C_7H_8N_4O_2 \cdot H_2O$ 198.18

$C_7H_8N_4O_2$ 180.17

1*H*-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, monohydrate;

Theophylline monohydrate CAS RN®: 5967-84-0; UNII: C137DTR5RG.

Anhydrous CAS RN®: 58-55-9; UNII: 0I55128JYK.

DEFINITION

Theophylline contains one molecule of water of hydration or is anhydrous. It contains NLT 97.0% and NMT 102.0% of theophylline ($C_7H_8N_4O_2$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- A. ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#) ▲ (CN 1-MAY-2020)
- B. The retention time of the major peak of the *Sample* solution corresponds to that of the *Standard* solution, as obtained in the Assay.

ASSAY

• PROCEDURE

Solution A: 10 mM ammonium acetate prepared as follows. Transfer 770.8 mg of ammonium acetate to a 1-L volumetric flask, and dissolve in 80% flask volume of water. Adjust with glacial acetic acid to a pH of 5.5 and dilute with water to volume. Pass through a suitable filter of 0.2- μ m pore size.

Solution B: Methanol

Mobile phase: See [Table 1](#).

Table 1

| Time (min) | Solution A (%) | Solution B (%) |
|---------------|-------------------|-------------------|
| 0 | 98 | 2 |
| 7 | 50 | 50 |
| 7.3 | 10 | 90 |
| 8.3 | 10 | 90 |
| 8.31 | 98 | 2 |
| 12 | 98 | 2 |

Impurity stock solution: 0.2 mg/mL of [USP Theophylline Related Compound F RS](#) in water

System suitability solution: 1 mg/mL of [USP Theophylline RS](#) and 1 µg/mL of [USP Theophylline Related Compound F RS](#), from *Impurity stock solution*, in water. Sonicate as needed to aid in the dissolution.

Standard solution: 0.2 mg/mL of [USP Theophylline RS](#) in water

Sample solution: 0.2 mg/mL of Theophylline in water

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 270 nm

Column: 2.1-mm × 10-cm; 1.7-µm packing L1

Column temperature: 40°

Flow rate: 0.4 mL/min

Injection volume: 1 µL

System suitability

Samples: System suitability solution and Standard solution.

[NOTE—See [Table 2](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 1.5 between theophylline and theophylline related compound F, System suitability solution

Relative standard deviation: NMT 0.73%, Standard solution

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of theophylline ($C_7H_8N_4O_2$) in the portion of Theophylline taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of theophylline from the Sample solution

r_S = peak response of theophylline from the Standard solution

C_S = concentration of [USP Theophylline RS](#) in the Standard solution (mg/mL)

C_U = concentration of Theophylline in the Sample solution (mg/mL)

Acceptance criteria: 97.0%–102.0% on the dried basis

IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.15%

• [ORGANIC IMPURITIES](#)

Solution A, Solution B, Mobile phase, Impurity stock solution, and System suitability solution: Proceed as directed in the Assay.

Standard stock solution: 50 µg/mL each of [USP Caffeine RS](#), [USP Theophylline RS](#), [USP Theophylline Related Compound B RS](#), [USP Theophylline Related Compound C RS](#), [USP Theophylline Related Compound D RS](#), and [USP Theophylline Related Compound F RS](#)

Standard solution: 1 µg/mL each of [USP Caffeine RS](#), [USP Theophylline RS](#), [USP Theophylline Related Compound B RS](#), [USP Theophylline Related Compound C RS](#), [USP Theophylline Related Compound D RS](#), and [USP Theophylline Related Compound F RS](#), from Standard stock solution, in water

Sample solution: 1.0 mg/mL of Theophylline in water

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector

For unspecified impurities with absorption maxima near 220 nm: UV 220 nm

For specified impurities and unspecified impurities with absorption maxima near 270 nm: UV 270 nm

Column: 2.1-mm × 10-cm; 1.7-µm packing L1

Column temperature: 40°

Flow rate: 0.4 mL/min

Injection volume: 1 µL

System suitability

Samples: System suitability solution and Standard solution

[NOTE—See [Table 2](#) for relative retention times.]

Suitability requirements

Resolution: NLT 1.5 between theophylline and theophylline related compound F, *System suitability solution*

Relative standard deviation: NMT 3.0% for each peak present in the *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

For impurities detected at 270 nm

Calculate the percentage of caffeine, theophylline related compound B, theophylline related compound C, and theophylline related compound D in the portion of Theophylline taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of caffeine, theophylline related compound B, theophylline related compound C, or theophylline related compound D from the *Sample solution*

r_s = peak response of the corresponding Reference Standard from the *Standard solution*

C_s = concentration of [USP Caffeine RS](#), [USP Theophylline Related Compound B RS](#), [USP Theophylline Related Compound C RS](#), or [USP Theophylline Related Compound D RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Theophylline in the *Sample solution* (mg/mL)

Calculate the percentage of any other individual unspecified impurity with absorption maxima near 270 in the portion of Theophylline taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of any other individual unspecified impurity from the *Sample solution*

r_s = peak response of theophylline from the *Standard solution*

C_s = concentration of [USP Theophylline RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Theophylline in the *Sample solution* (mg/mL)

For impurities detected at 220 nm

Calculate the percentage of any other individual unspecified impurity with absorption maxima near 220 in the portion of Theophylline taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of any other individual unspecified impurity from the *Sample solution*

r_s = peak response of theophylline from the *Standard solution*

C_s = concentration of [USP Theophylline RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Theophylline in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). Disregard peaks less than 0.05%.

Table 2

| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
|---------------------------------|-------------------------|------------------------------|
| Theophylline related compound C | 0.36 | 0.10 |
| Theophylline related compound B | 0.63 | 0.10 |
| Theophylline related compound D | 0.69 | 0.10 |

| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
|--|-------------------------|------------------------------|
| Theophylline | 1.0 | — |
| Theophylline related compound F ^a | 1.09 | — |
| Caffeine | 1.20 | 0.10 |
| Any other individual unspecified impurity | — | 0.10 |
| Total impurities | — | 0.5 |

^a Included for establishing system suitability only.

SPECIFIC TESTS

- [Loss on Drying \(731\)](#)

Analysis: Dry at 105° for 4 h.

Acceptance criteria: The hydrous form loses 7.5%–9.5% of its weight, and the anhydrous form loses NMT 0.5% of its weight.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.
- **LABELING:** Label it to indicate whether it is hydrous or anhydrous.
- [USP Reference Standards \(11\)](#)

[USP Caffeine RS](#)

[USP Theophylline RS](#)

[USP Theophylline Related Compound B RS](#)

3-Methyl-1*H*-purine-2,6-dione.

C6H6N4O2 166.14

[USP Theophylline Related Compound C RS](#)

N-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)formamide.

C7H10N4O3 198.18

[USP Theophylline Related Compound D RS](#)

Theophyllidine;

N-Methyl-5-(methylamino)-1*H*-imidazole-4-carboxamide hydrochloride monohydrate.

C6H10N4O.HCl.H2O 208.65

[USP Theophylline Related Compound F RS](#)

Etophylline;

7-(2-Hydroxyethyl)-1,3-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione.

C9H12N4O3 224.22

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|----------------------------|---|---------------------------|
| THEOPHYLLINE | Documentary Standards Support | SM52020 Small Molecules 5 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | SM52020 Small Molecules 5 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(3)

Current DocID: GUID-9CDF5798-380A-490A-B56F-D2BB9ABBE39E_2_en-US

DOI: https://doi.org/10.31003/USPNF_M82120_02_01

OFFICIAL